Search

    Language Settings
    Select Website Language

    GDPR Compliance

    We use cookies to ensure you get the best experience on our website. By continuing to use our site, you accept our use of cookies, Privacy Policy, and Terms of Service.

    Argenx Announces FDA Acceptance Of Supplemental Biologics License Application With Priority Review For VYVGART In Achr-Ab Seronegative Gmg

    2 days ago

    (MENAFN - GlobeNewsWire - Nasdaq) January 13, 2026, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of ...
    Click here to Read More
    Previous Article
    Textmagic Group's Sales Results For Q4 2025
    Next Article
    Ontex Accelerates CEO Transition, Launches Strategic Review And Appoints Lorenzo Grabau To The Board

    Related World Updates:

    Are you sure? You want to delete this comment..! Remove Cancel

    Comments (0)

      Leave a comment